MOA Life Plus Co. Ltd. Logo

MOA Life Plus Co. Ltd.

Develops immunotherapies & consumer solutions for immunity, skin rejuvenation, and pet care.

142760 | KO

Overview

Corporate Details

ISIN(s):
KR7142760008
LEI:
Country:
South Korea
Address:
경기도 용인시 수지구 신수로 767 7층 (동천동, 분당수지유타워 지식산업센터), 용인시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MOA Life Plus Co. Ltd. (formerly BioLeaders Corp.) is a biopharmaceutical and healthcare company focused on developing innovative treatments and consumer products. The company's pharmaceutical division develops biopharmaceuticals, including immunotherapies, cancer treatments, and vaccines, utilizing a proprietary platform technology based on poly-gamma-glutamic acid (γ-PGA) and probiotics to enhance immune responses. Its clinical pipeline includes candidates for conditions such as cervical cancer and muscular dystrophy. The consumer business division provides tailored, clinically researched solutions for immunity enhancement, skin rejuvenation, and pet healthcare. The company supports its innovations with an extensive portfolio of domestic and international patents.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Capital/Financing Update
[기재정정]주요사항보고서(자기전환사채매도결정)
Korean 45.4 KB
2025-08-18 00:00
Legal Proceedings Report
파생상품거래손실발생
Korean 6.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-08-11 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 7.6 KB
2025-07-29 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 11.8 KB
2025-07-24 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 12.2 KB
2025-07-24 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 11.2 KB
2025-07-24 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 72.5 KB
2025-07-24 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 37.3 KB
2025-07-18 00:00
Capital/Financing Update
타인에대한채무보증결정
Korean 20.0 KB
2025-07-18 00:00
Related Party Transaction
[기재정정]타인에대한채무보증결정
Korean 24.4 KB
2025-07-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 70.8 KB
2025-07-02 00:00
Share Issue/Capital Change
전환가액의조정
Korean 16.6 KB
2025-07-01 00:00
Share Issue/Capital Change
전환청구권행사
Korean 12.9 KB
2025-06-26 00:00
Delisting Announcement
해산사유발생(종속회사의주요경영사항)
Korean 9.2 KB

Automate Your Workflow. Get a real-time feed of all MOA Life Plus Co. Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MOA Life Plus Co. Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MOA Life Plus Co. Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.